Epstein-Barr virus seroepidemiology in China

Area of Science:

• Oncology
• Immunology
• Epidemiology

Background:

• Nasopharyngeal carcinoma (NPC) is a significant health concern in high-risk areas.
• Early diagnosis of NPC is crucial for improving patient outcomes.
• Serological markers can aid in early cancer detection.

Purpose of the Study:

• To evaluate the effectiveness of screening for immunoglobulin A viral capsid antigen (IgA VCA) antibody for early nasopharyngeal carcinoma (NPC) detection.
• To assess the diagnostic yield and prognostic value of IgA VCA antibody screening in prospective studies.
• To analyze changes in IgA VCA antibody titers over time in relation to NPC development.

Main Methods:

• Serological screening of over 300,000 sera from individuals in NPC high-risk areas.
• Prospective studies involving screening of specific age groups (e.g., over 40) and follow-up.
• Monitoring of IgA VCA antibody titers in antibody-positive and antibody-negative individuals over several years.

Main Results:

• Screening identified a high proportion of NPC cases in early stages (Stage I: 38.5%, Stages I+II: 92.3%) compared to outpatient clinics.
• IgA VCA antibody was detectable up to 5 years before NPC diagnosis, with a detection rate 38-374 times higher than general population incidence.
• NPC patients were predominantly detected in groups with stable or increasing IgA VCA antibody titers; no NPC cases arose in the initially antibody-negative group.

Conclusions:

• Serological screening for IgA VCA antibody is a highly effective method for early detection of nasopharyngeal carcinoma (NPC) in high-risk populations.
• The presence and changes in IgA VCA antibody titers provide valuable prognostic information for NPC.
• This screening approach significantly enhances the detection rate of NPC at early, more treatable stages.